First published 9/28/2026, 9:16:15 AM · Last updated 9/28/2026, 9:16:15 AM

Efficacy and safety of third-generation EGFR-TKI rechallenge therapy in advanced non-small cell lung cancer patients with EGFR mutation: a retrospective cohort study

Journal article published 2026-09-01 reporting a retrospective cohort study on third-generation EGFR-TKI rechallenge therapy in advanced non-small cell lung cancer patients with EGFR mutation. The supplied excerpt includes only publisher and content type and does not provide study methods, results, or conclusions.

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 2/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 2/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 2/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 5/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 1/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

Results may be relevant to clinicians and researchers treating advanced non-small cell lung cancer with EGFR mutations.

Sources

Efficacy and safety of third-generation EGFR-TKI rechallenge therapy in advanced non-small cell lung cancer patients with EGFR mutation: a retrospective cohort study

Report an issue